Incannex Healthcare Inc. (IXHL): Operating Income
-$23.03M
Year ended 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | -$23.03M | n/m | 2026-09-25, From 2025-07-01 |
| 2025-06-30 | -$23.79M | n/m | 2026-09-25, From 2024-07-01 |
| 2024-06-30 | -$30.04M | n/m | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | -$49.67M | n/a | 2024-09-30, From 2022-07-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | -$23.03M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.05B | +18.0% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$4.39M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $24.74M | +23.1% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | -$5.29M | n/m |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.21M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$2.54M | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $2.16B | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $231.0K | n/m |
Compare IXHL, ABT, TXMD, NATR side by side · Screen every company in Pharmaceutical Preparations ↗